Geode Capital Management LLC Purchases 73,484 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

Geode Capital Management LLC increased its position in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,053,178 shares of the company’s stock after acquiring an additional 73,484 shares during the quarter. Geode Capital Management LLC owned about 2.07% of Cardlytics worth $3,371,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GSA Capital Partners LLP lifted its holdings in shares of Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after purchasing an additional 354,474 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after acquiring an additional 307,800 shares in the last quarter. RBF Capital LLC increased its holdings in shares of Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after acquiring an additional 369,620 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Cardlytics in the 3rd quarter valued at approximately $45,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Cardlytics in the 3rd quarter worth approximately $153,000. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on CDLX. Evercore ISI initiated coverage on Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.92.

Cardlytics Price Performance

Shares of NASDAQ CDLX opened at $3.49 on Tuesday. Cardlytics, Inc. has a one year low of $2.89 and a one year high of $20.52. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a fifty day moving average of $3.91 and a 200 day moving average of $4.81. The firm has a market cap of $177.37 million, a PE ratio of -0.57 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. During the same quarter last year, the business posted ($0.26) earnings per share. The business’s quarterly revenue was down 15.1% compared to the same quarter last year. As a group, research analysts predict that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Insider Transactions at Cardlytics

In related news, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares in the company, valued at approximately $687,298.15. The trade was a 11.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alexis Desieno sold 8,854 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the completion of the sale, the chief financial officer now directly owns 121,976 shares in the company, valued at $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,007 shares of company stock valued at $251,297. Corporate insiders own 4.40% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.